The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma

Kei Nakagawa, Yu Katayose, Toshiki Rikiyama, Adoru Okaue, Michiaki Unno

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Surgical resection is the gold standard of treatment for cholangiocarcinoma. However, there are also many recurrences after operation, because of the anatomical background and the tendency of invasion. We thought that eliminating the remnant of the cancer could yield a better prognosis. Therefore, an introduction of the neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma patient (NACRAC) was planned. The safety of NAC-RAC was confirmed by a pilot study. The recommended dose of gemcitabine (600 mg/m2) was determined by a phase I study. A phase II study is now being performed for evaluating the effectiveness and safety. NACRAC may control the frontal part of the tumor with difficult distinctions made by MDCT, and abolishing the cancer remnant is expected. The possibility of extended prognosis by NACRAC can be considered.

Original languageEnglish
Pages (from-to)2009-2011
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number12
Publication statusPublished - 2009 Nov

Keywords

  • Cholangiocarcinoma
  • Gemcitabine
  • Neoadjuvant chemoradiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this